Application of salt engineering to reduce/mask bitter taste of clindamycin

References

• Milne CP, Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clin Ther. 2008;30(11):2133–2145.
   PubMed Web of Science ®Google Scholar
• Roberts R, Rodriguez W, Murphy D, et al. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA. 2003;290(7):905–911.
   PubMed Web of Science ®Google Scholar
• Ren Z, Zajicek A. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: what can the obstetric community learn from the pediatric experience? Semin Perinatol. 2015;39(7):530–531.
   PubMed Web of Science ®Google Scholar
• Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev Indi Pharm. 2004;30(5):429–448.
   PubMed Web of Science ®Google Scholar
• Cantor SL, Khan MA, Gupta A. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of clindamycin hydrochloride. Drug Dev Ind Pharm. 2015;41(7):1156–1164.
   PubMed Web of Science ®Google Scholar
• Joshi S, Petereit HU. Film coatings for taste masking and moisture protection. Int J Pharm. 2013;457(2):395–406.
   PubMedGoogle Scholar
• Arima H, Higashi T, Motoyama K. Improvement of the bitter taste of drugs by complexation with cyclodextrins: applications, evaluations and mechanisms. Ther Deliv. 2012;3(5):633–644.
   PubMedGoogle Scholar
• Patel AR, Vavia PR. Preparation and evaluation of taste masked famotidine formulation using drug/beta-cyclodextrin/polymer ternary complexation approach. AAPS PharmSciTech. 2008;9(2):544–550.
   PubMed Web of Science ®Google Scholar
• Rahman Z, Zidan AS, Khan MA. Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation. Int J Pharm. 2010;400(1–2):49–58.
   PubMedGoogle Scholar
• Rahman Z, Zidan AS, Khan SR, et al. Cholorpheniramine tannate complexes: physicochemical, chemometric, and taste masking evaluation. Int J Pharm. 2012;436(1–2):582–592.
   PubMedGoogle Scholar
• Rahman Z, Zidan AS, Berendt RT, et al. Tannate complexes of antihistaminic drug: sustained release and taste masking approaches. Int J Pharm. 2012;422(1-2):91–100.
   PubMedGoogle Scholar
• Rahman Z, Zidan AS, Samy R, et al. Improvement of physicochemical properties of an antiepileptic drug by salt engineering. AAPS PharmSciTech. 2012;13(3):793–801.
   PubMed Web of Science ®Google Scholar
• Rahman Z, Siddiqui A, Khan MA. Orally disintegrating tablet of novel salt of antiepileptic drug: formulation strategy and evaluation. Eur J Pharm Biopharm. 2013;85(3):1300–1309.
   PubMed Web of Science ®Google Scholar
• Bhise K, Shaikh S, Bora D. Taste mask, design and evaluation of an oral formulation using ion exchange resin as drug carrier. AAPS PharmSciTech. 2008;9(2):557–562.
   PubMed Web of Science ®Google Scholar
• Karaman R. Prodrugs for masking bitter taste of antibacterial drugs-a computational approach. J Mol Model. 2013;19(6):2399–2412.
   PubMed Web of Science ®Google Scholar
• Vaziri A, Warburton B. Slow release of chloroquine phosphate from multiple taste-masked W/O/W multiple emulsions. J Microencapsul. 1994;11(6):641–648.
   PubMed Web of Science ®Google Scholar
• Zidan AS, Rahman Z, Khan MA. Product and process understanding of a novel pediatric anti-HIV tenofovir niosomes with a high-pressure homogenizer. Eur J Pharm Sci. 2011;44(1-2):93–102.
   PubMed Web of Science ®Google Scholar
• Smieja M. Current indications for the use of clindamycin: A critical review. Can J Infect Dis. 1998;9(1):22–28.
   PubMedGoogle Scholar
• Cleocin FDA label. [cited 2018 Aug 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/50162s100lbl.pdf
   Google Scholar
• Cleocin Pediatric® FDA label. [cited 2018 Aug 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/062644s015lbl.pdf
   Google Scholar
• de Groot MCH, van Puijenbroek EP. Clindamycin and taste disorders. Br J Clin Pharmacol. 2007;64(4):542–545.
   PubMed Web of Science ®Google Scholar
• Zajicek A, Fossler MJ, Barrett JS, et al. A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms. AAPS J. 2013;15(4):1072–1081.
   PubMed Web of Science ®Google Scholar
• Alayoubi A, Daihom B, Adhikari H, et al. Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin Amberlite IRP 69 for use in pediatrics. Drug Dev Ind Pharm. 2016;42(10):1579–1589.
   PubMed Web of Science ®Google Scholar
• D’Arcy PF. Adverse reactions to excipients in pharmaceutical formulations. In: Florence AT, Salole EG, editors. Formulation factors in adverse reactions. London: Wright; 1990. p. 1–22.
   Google Scholar
• Schmähl D, Habs M. Investigations on the carcinogenicity of the artificial sweeteners sodium cyclamate and sodium saccharin in rats in a two-generation experiment. Arzneimittelforschung. 1984;34(5):604–606.
   PubMed Web of Science ®Google Scholar
• Cyclamate monographs, International Agency for Research on Cancer-Cyclamate monographs, WHO, 1999. Volume 7.
   Google Scholar
• Lawrence JF.Saccharin in encyclopedia of food sciences and nutrition. 2nd ed. Cambridge (MA): Academic Press; 2003. p. 5033–5035.
   Google Scholar
• Renwick AG, Williams RT. The fate of cyclamate in man and other species. Biochem J. 1972;129(4):869–879.
   PubMed Web of Science ®Google Scholar
• Connors KA, Amidon GA, Stella VJ. Chemical stability of pharmaceuticals: A handbook for pharmacists. 2nd ed. New York (NY): John Wiley and Sons; 1986. p. 365–370.
   Google Scholar
• Barakh Ali SF, Rahman Z, Dharani S, et al. Chemometric models for quantification of carbamazepine anhydrous and dihydrate forms in the formulation. J Pharm Sci. 2019;108(3):1211–1219.
   PubMed Web of Science ®Google Scholar
• Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727.
   PubMedGoogle Scholar
• Dharani S, Barakh Ali SF, Afrooz H, et al. Development and validation of a discriminatory dissolution method for rifaximin products. J Pharm Sci. 2019;108(6):2112–2118.
   Google Scholar
• ICH harmonized tripartite guideline—Validation of analytical procedures: Text and methodology Q2 (R1), 2005.
   Google Scholar
• Rahman Z, Dharani S, Barakh Ali SF, et al. Effect of processing parameters and controlled environment storage on the disproportionation and dissolution of extended-release capsule of phenytoin sodium. Int J Pharm. 2018;550(1-2):290–299.
   PubMedGoogle Scholar
• Daihom B, Alayoubi A, Ma D, et al. Development and physicochemical characterization of clindamycin resinate for taste masking in pediatrics. Drug Dev Ind Pharm. 2016;42(10):1600–1608.
   PubMed Web of Science ®Google Scholar
• Regulatory classification of pharmaceutical co-crystals guidance for industry, 2018.
   Google Scholar
• USP41-NF36. Clindamycin hydrochloride capsules, 2018, page 993.
   Google Scholar
• FDA guidance for industry-Dissolution testing of immediate release solid oral dosage forms, 1997.
   Google Scholar